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Nephroureterectomy is currently the gold standard for management of upper urinary tract urothelial carcinoma despite it results.
This review article in the loss of a renal unit. The ultimate aim of endoscopic management of this condition is cancer control
whilst preserving renal function and the integrity of the urinary tract. Endoscopic treatments of upper tract TCC include the
antegrade percutaneous and retrograde ureteroscopic approaches. This review article summarizes the endoscopic management
of upper tract urothelial carcinoma, surveillance of the disease after endoscopic management and adjuvant therapy. The main
message regarding endoscopic management of upper tract urothelial cancer is that patients must be carefully selected. Patient
selection is based on tumour size, grade, and multifocality. Single low-grade tumours, less than 1.5 cm in size, generally have
a good outcome with endoscopic treatment provided that they have regular ureteroscopic surveillance. Ureteroscopic treatment
of high-grade tumours is essentially palliative. It is essential that patients are motivated and compliant as lifetime follow-up is
necessary. However, until large randomized trials with long-term follow-up are performed, endoscopic management cannot be
considered a standard treatment and should be limited to poor performance status patients.
Copyright © 2009 K. Moore et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Primary urothelial carcinoma of the upper urinary tract
accounts for 5% of all urothelial tumours and 7–10%
of all kidney tumours. Nephroureterectomy including a
cuﬀ of bladder has been the “gold standard” treatment
despite the associated morbidity and loss of a renal unit.
Currently, laparoscopic approaches have reduced the size of
the incision, length of hospital stay, postoperative pain, and
morbidity and give oncological outcomes similar to those
of open surgery. However, a laparoscopic nephroureterec-
tomy is still radical surgery that does not spare the renal
parenchyma.
The ultimate aim of endoscopic management is cancer
control whilst preserving renal function and the integrity of
the urinary tract. These procedures were initially reserved
for patients with solitary kidneys, bilateral disease, or renal
insuﬃciency but are starting to gain acceptance in the man-
agement of small, low-stage, low-grade tumours in patients
with normal contralateral kidneys. Endoscopic treatment
of the upper urinary tract includes antegrade percutaneous
and retrograde ureteroscopic approaches which were ﬁrst
described in the mid 1980s.
2. Tumour GradeandStage
A key point in choosing the optimum treatment for upper
tract urothelial carcinoma is correct staging by endoscopic
evaluation and biopsy. There are signiﬁcant diﬀerences in 5
year survival rates ranging from 60–90% in Ta/1 and CIS
disease to only 5% in T3/4 disease. The most important
factorsforsurvivalaretumourstage,grade,andmultifocality
[1].
In a study of 130 consecutive nephroureterectomy spec-
imens, tumour stage signiﬁcantly correlated with tumour
grade. Five percent of patients with low-grade UTUC had
pathologic stage pT2 or higher, while 65% of patients with
high-grade tumours had pathologic stage pT2 or higher [2].
Similarly,Murphyetal.reportedthat47of49patients(96%)
with grade 1 upper tract transitional cell carcinoma also had
stage 1 disease [3].
Tumour grade is also related to recurrence rate with
Zincke reporting that only 5% of 21 patients with grade 1 or
2developedarecurrencecomparedwith50%withgrade3or
4disease[4].Orihelareportedthatin14patientsrecurrences
were almost exclusively in those with multifocal, high-grade,
invasive tumours [5]. In general, recurrences are unlikely in2 Advances in Urology
patientswithsingle,lowgradesmalltumoursconﬁnedtothe
mucosa with no history of concurrent urothelial tumours
elsewhere in the urinary tract. Upper tract recurrence rates
were 28.5% in a group with a history of bladder lesions
compared to 16.6% in a group without bladder disease [6].
However, diagnosis of ureteric lesions is not straight
forward. In a study by El-Hakim et al., ureteroscopic
appearances of upper tract urothelial carcinoma was only
70% accurate in determining the grade and they suggested
biopsies must be taken to in order to determine the true
grade [7]. In contrast, a study by Keeley et al. showed
transitional cell carcinoma grade on ureteroscopy accurately
predicted tumour grade and stage in the surgical specimens.
They observed that, of the 30low or moderate grade uretero-
scopic specimens, 27 (90%) proved to be low or moderate
grade transitional cell carcinoma in the surgical specimens,
while 11 of 12 high grade ureteroscopic specimens (91.6%)
proved to be high grade transitional cell carcinoma (P<
.0001).In30lowormoderategradeureteroscopicspecimens,
26 (86.6%) had a low stage (Ta or T1) tumour. In contrast,
8 of 12 high grade ureteroscopic specimens (66.7%) had
invasive tumour (stage T2 or T3) in the surgical specimen
(P = .0006) [8]. These same authors also noted how
crucial the techniques for handling and processing the small
samples obtained via ureteroscopy are. They found that
sending multiple samples, including saline washes before
and after biopsy, improved the ability to grade tumours
ureteroscopically from 42.9% to 90% [8].
A further study by Williams et al. to determine the accu-
racy of ureteroscopic biopsy in predicting the histopathology
of upper tract TCC looked at 30 biopsies taken between
1998 and 2006. At nephroureterectomy, 2 cases were found
to have no tumour. Of the remaining 28 cases, the biopsy
grade proved to be identical in 21 (75%). 17 of 25 (68%)
of grade 1-2 ureteroscopic specimens had a low stage (T0,
Ta, or T1) tumour. In contrast, 3 of 5 (60%) high grade
specimens had invasive tumour (T2 or T3). They concluded
that ureteroscopic inspection and biopsy provided accurate
information regarding the grade and stage of upper tract
TCC [9].
Tumour size also appears to inﬂuence recurrence rate.
One study reported that only 7 of 19 renal units (36%) with
tumours larger than 1.5cm were ever rendered tumour free
and 3 of 6 tumour free renal units subsequently developed
a recurrence. In contrast, 20 of 22 (91%) of renal units
with initial tumours less than 1.5cm were rendered tumour
free and only 5 (25%) tumour free kidneys had recurrences
[10]. This ﬁnding was echoed by Johnson et al. who found
that patients presenting with tumours >1.5cm in size had
a higher incidence of recurrence and recurred earlier [11].
Johnson et al. conﬁrmed the aggressive nature of high grade
disease. In a cohort of 63 patients, tumour progression was
seen in 83% of patients with high grade ureteric urothelial
carcinoma when nephroureterectomy was not performed
[11].
3. Ureteroscopic Management
Developments in ureteroscopic instruments and techniques
now allow for ureteroscopic access to the entire upper uri-
nary tract. Small diameter rigid and ﬂexible ureteroscopies
with greater deﬂecting abilities have been combined with
endoscopic biopsy techniques and devices for tissue ablation
to oﬀer practical approaches to upper urinary tract tumours.
Particularly, the holmium:YAG and neodymium:YAG lasers
used to cauterize and ablate tumours, delivered through
small-diameter, ﬂexible ﬁbres, have allowed treatment of
relatively large tumours whilst maintaining homeostasis
[11]. Electrosurgical techniques were ﬁrst used for the
treatment of ureteric neoplasms. They are used in a similar
way to resectoscopes for other procedures but because of the
rigid design of the resectoscope, its use is primarily conﬁned
to the distal ureter. Given the thin wall of the ureter, care
should be taken to avoid resecting through the full thickness
of the wall and also to avoid fulgurating a large area of the
ureter as this increases the chances of subsequent stricture
formation. Simple fulguration with an electrocautery probe
is another electrosurgical technique suitable for very small
lesionsorforthebaseofthetumourafterremovalofthebulk
of the lesion [12].
The neodymium:YAG laser has been used widely for the
treatment of both bladder and upper tract tumours. The
ﬁbre is directed at and placed in close approximation to the
tumour, activated at 20 to 30w and moved over the surface
to coagulate the tissue. The laser penetrates to a depth of
5-6mm. The coagulated tissue is removed with graspers to
expose further portions of the tumour which can be treated
in the same fashion.
The holmium:YAG laser both coagulates and ablates
tissue penetrating to a depth of 0.5mm. This is useful for
ureteric lesions as it can ablate and remove an occlusive
tumour opening up the lumen. Irrigation is needed to clear
the visual ﬁeld of tissue debris during treatment.
The two lasers can be used in combination. The
neodymium:YAG laser, penetrating to a depth of several
millimetres, is used to coagulate the major volume of the
tumour, then the coagulated tissue can be removed with the
holmium:YAG laser [12].
Schmeller compared laser ablation with electrocautery
and found fewer strictures developed in the laser group
[13]. However, Martinez-Pineiro et al. found that their laser
results did not oﬀer signiﬁcant beneﬁt compared with elec-
trocautery [6]. Data on electrocautery versus laser treatment
is scant (probably due to the small cohort of patients being
treated in this manner) but to date there is no convincing
evidence that the eﬃcacy of tumour destruction is aﬀected
by the method used.
All ureteroscopic interventions should be followed with
short term ureteral stenting to prevent any postoperative
obstructive sequelae [12].
Complications of ureteroscopic management occur in 8–
13% and are mostly minor including perforation in 1-4%
(managed by ureteric stenting or percutaneous drainage)
and ureteric strictures in 4.9–13.6%. Most strictures can be
managed by stenting, laser incision, or balloon dilatation
[14].
In a study by Keeley et al., between 1985 and 1995,
92 patients were diagnosed with upper tract TCC. 46 had
a diagnostic ureteroscopy followed by open extirpationAdvances in Urology 3
and 46 had some form of endoscopic treatment. 8/46
had open surgery following endoscopic therapy and 38
(41 kidneys) had ureteroscopic treatment and follow-up.
Semirigid and ﬂexible ureteroscopes were used to examine
the collecting system, tumours were biopsied then treated
with fulguration, the neodymium:YAG laser and/or the
holmium:YAG laser. Patients were treated every 6 to 12
weeks until tumour free and then followed up with further
ureteroscopy. At least 1 follow-up ureteroscopic examination
was performed in all 38 patients. Of the 41 renal units,
28 (68%) were rendered tumour free after an average of
1.57 ureteroscopic treatments. Complications were generally
related to comorbid disease, 1 patient with a solitary
kidney developed an episode of acute renal failure with
clot retention but recovered to baseline renal function. No
patient required a blood transfusion or emergency open
surgery for bleeding. 2 patients had ureteric strictures, 1
with a history of pelvic radiotherapy for bladder cancer and
1 following neodymium:YAG laser treatment of a proximal
ureteric tumour. No ureteric perforations were noted [10].
Chen and Bagley followed 23 patients with a normal
contralateral kidney for a mean of 35 months after initial
ureteroscopic treatment of upper tract transitional cell
carcinoma (range 8 to 103). 22 tumours were grade 1 to
2 and 1 was grade 2 to 3. There were multiple recurrences
(treated ureteroscopically) in 15 of 23 patients (65%) and no
r e c u r r e n c e si n8( 3 5 % ) .A v e r a g et i m et or e c u r r e n c ew a s9 . 5
months (range 2 to 53) with an average of 4 recurrences (1 to
14). There were no metastases or mortality from transitional
cell carcinoma. At completion of the study, 4 patients (17%)
had persistent disease and 4 (17%) elected to undergo
nephroureterectomy. Complications included ureteral stric-
tures in 2 patients treated for distal ureteral tumours. The
strictures were treated with endoscopic dilation [15].
A study from Madrid reported a failure of ureteroscopy
in 11 of 39 patients (28.2%), mainly due to inability to
reach pelvic tumours or to destroy the tumour. Four of
these patients were successfully treated by a percutaneous
approach and 7 required nephroureterectomy [6]. Similarly,
Blute et al. reported a high ureteroscopic failure rate in 14/22
(63.6%) of patients with renal pelvic tumours, indicating
that ureteroscopy is not the best procedure for most tumours
oftherenalpelvisandthattheseneoplasmsarebestmanaged
percutaneously [16].
4. PercutaneousNephroscopic Management
Although ureteroscopy has the theoretical beneﬁt of pre-
serving a closed urinary system, percutaneous access may be
necessary when tumours are not accessible via a retrograde
route or for larger tumours. Percutaneous nephroscopy
oﬀers better visualisation of the renal pelvis while accommo-
dating larger calibre instruments capable of handling a larger
tumour burden [12].
After establishing a percutaneous tract, the lesion is
initially biopsied and then bebulked. As there is a larger
access tract, cold cup biopsy forceps can be used through a
standard nephroscope or a cutting loop from a resectoscope.
The base of the lesion is resected and sent for histological
evaluation and haemostasis is achieved by electrocauterey
or laser ablation as previously described. The established
nephrostomy tract can be maintained, allowing for repeated
treatmentoradministrationoftopicaladjuvanttherapy[12].
Complication rates with the percutaneous approach
are low and include blood transfusion in <20% and less
commonly, PUJ obstruction from stricture, adjacent organ
injury, and pleural injury [1]. Tumour seeding along the
nephrostomy tract has been reported [17]. Larger series
though, failed to ﬁnd tract recurrences conﬁrming that this
phenomenon is rare. Precautions suggested to minimize
seeding include use of an Amplatz sheath to decrease
intrarenal pressure during manipulations and immediate
irrigation of the collecting system and percutaneous tract
with a 5-ﬂorouracil solution. One author suggested placing
a radioactive iridium wire in the percutaneous tract [18].
Goel et al. reported on 5 year outcomes of 24 patients
who underwent primary percutaneous resection of the
urothelial tumour. Patients with low stage pT0-1 disease
were treated primarily with percutaneous surgery. Patients
with multi-segmental pelvicaliceal system involvement, stage
greater than pT1, high grade histology or additional ureteral
tumours were considered for nephroureterectomy. Topical
chemotherapy (mitomycin C or epirubicin) was adminis-
tered via nephrostomy tube or intravesical instillation after
Double-J stent insertion. Surveillance included upper tract
cytology, nephroscopy or ﬁberoptic ureterorenoscopy.
Of the 24, 2 cases had squamous cell carcinoma, 5 had
grade 3 transitional cell carcinoma, 15 had grade 1 to 2
transitional cell carcinoma and 2 had no tumour. Control
was established with initial percutaneous resection in 18
(75%) cases and second look nephroscopy in 4. All patients
with high-grade disease died of malignancy except one (with
no further treatment) and 6 of the 15 patients with low-
grade noninvasive transitional cell carcinoma underwent
nephroureterectomy during follow-up either due to progres-
sion of disease, concomitant tumour, or complications. Two
patients with solitary kidneys died of renal failure unrelated
to malignancy. High grade tumours or tumours greater
than T1 were treated with nephroureterectomy early during
management. There was no perioperative mortality and in 9
(60%) of the low-grade cases the kidneys were preserved at
mean follow-up [19].
In a more recent study, Palou et al. retrospectively
reviewed 34 patients who had percutaneous management
of their upper tract TCC. 15% had grade 3 tumours with
either a solitary kidney or bilateral disease. During a 4.25-
year follow-up, recurrence was found in 44% at a median
time of 24 months. 9 cases required nephroureterectomy.
Renalpreservationwasachievedin74%.Overallsurvivaland
cancer speciﬁc survival was 71% and 93%, respectively [20].
Rouprˆ et et al. reported on the results of 24 patients
who underwent a percutaneous approach to their tumour.
Median follow-up was 62 months with recurrences detected
in 8/24 at a median time of 17 months. 3 recurrences were
in the ipsilateral ureter, 1 in the contralateral ureter, and 4
in the bladder. Five patients with high grade and/or invasive
tumour subsequently underwent an open nephroureterec-
tomy,oneimmediatelyandtheothersduringfollow-up.5/244 Advances in Urology
(20.8%) of the patients have died, and 4 of these deaths
were attributed to disease progression. They reported 5-
year disease speciﬁc survival rates as 79.5% and tumour free
survival rates as 68%. 4 patients developed perioperative
complications; 3 required blood transfusion and 1 developed
a collection (which was managed with antibiotics) after
inadvertent puncture of the bowel [21].
5.Surveillance
Unlike traditional management with nephroureterectomy,
endoscopic treatment of upper tract TCC requires strict
ureteroscopic surveillance as both the ureteroscopic and
percutaneous approach are associated with a high risk of
ipsilateral recurrence. Endoscopic follow-up has been shown
to be more sensitive than radiological examination as IVU
m a ym i s su pt o7 5 %o fs m a l lr e c u r r e n c e s[ 9]. Surveillance
ureteroscopy is usually performed at 3 and 6 months, then
6 monthly for a year, then annually, and it requires a
counselled, well-motivated patients to strictly adhere to the
follow-up protocol. Surveillance needs to be performed for
an indeﬁnite time interval as recurrences have been reported
after 8 years of follow-up [22].
In an eﬀortto reducethe anaesthetic risks, costsand time
of surveillance, a study from New York reported on their 16
year experience of oﬃce-based ureteroscopy for surveillance
of TCC after initial endoscopic ablation. 10 patients were
treated with endoscopic ablation for TCC. A total of 67
( r a n g e1t o1 9p e rp a t i e n t )s u r v e i l l a n c eu r e t e r o s c o p i e s
were performed in the oﬃce setting. This procedure was
performed without anaesthetic (only lignocaine jelly to
the urethra) using a ﬂexible ureteroscope. This revealed
7 upper tract TCC recurrences in 5 patients. A thorough
ureteroscopic examination in the operating room revealed
that only one patient had more extensive disease than
was indicated in the oﬃce based ureteroscopy. All patients
tolerated the oﬃce based procedure well with minimal
discomfort. There were no acute complications [23].
Urinalysis with dipstick and microscopic examination is
an attractive surveillance tool as it is noninvasive, inexpen-
sive, and can be performed in an outpatient setting giving
an immediate result. In patients with recurrent upper tract
transitional cell carcinoma, urinalysis had a low sensitivity
(36.3%) but high speciﬁcity (90.6%) in detecting recurrent
disease. This low detection rate may be due to the low
grade nature of most upper tract transitional cell carcinomas
managed with local resection as low grade tumours are less
likely to shed diagnostic cells [24]. In a series by Xia, voided
cytologies were positive in 33% of grade 1, 71% of grade 2
and 100% of grade 3 upper tract tumours. In recent years
adjunct diagnostic techniques such as immunocytologic
staining or ﬂuorescence in situ hybridisation have been used
for evaluating the presence or absence of malignant cells in
urine [25].
6. AdjuvantTherapy
A substantial proportion of patients with endoscopically
managed upper tract urothelial carcinoma will develop a
recurrence. Adjuvant topical immunotherapy or chemother-
apies have been used in an attempt to reduce the risk of
tumour recurrence. The most commonly instilled agents are
mitomycin-C and BCG. Method of instillation, depending
on the approach to the tumour, can be performed via
a retrograde ureteral catheter or through a percutaneous
nephrostomy tube. Most published reports involve few
patients with short follow-up and a relatively high compli-
cation rate.
Orihuela and Smith found a lower recurrence rate
(16.6% versus 80%) in those patients treated with BCG
compared to those who did not recieve adjuvant treatment
but a further study by the same group showed no survival
advantage [5]. Sharpe et al. reported on the use of BCG
via retrograde ureteral catheters in 17 kidneys of 11 patients
with abnormal cytology. At a mean follow-up of 36 months
cytology had normalised in 8 of 11 patients. 1 patient
developed a fever and was treated with antituberculous
drugs. In a further study of 18 patients treated with BCG, 7
developed fever on 14 occasions and 1 patient died of sepsis
despite prophylactic IV antibiotics. In terms of eﬃcacy, no
signiﬁcant diﬀerence was found between the patients treated
with BCG and those who were not [26].
Keele et al. looked at 19 patients who underwent a
total of 28 treatments with mitomycin C after ureteroscopic
treatment for high volume, recurrent or multifocal disease.
Following 1 to 4 treatments with MMC, 11 of 19 (58%)
wererenderedfreeofdisease,4requirednephroureterectomy
for persistent or recurrent disease and no patients developed
local or distant progression of disease or any signiﬁcant
side eﬀects [26]. In a study that reported on 14 patients
who received MMC, one patient died of aplastic anaemia
and sepsis secondary to extravasation during treatment. This
same study also found a lower rate of recurrence among
patients treated with MMC or BCG compared to those
treated with thiotepa or oral 5-ﬂuorouracil [6].
As yet, no study has shown statistical improvement
regarding survival and recurrence rates and no protocol of
treatment has been accepted. Randomized multicenter trials
are needed to assess the eﬃcacy of adjuvant agents.
7. Endoscopic Treatment versusRadical
Nephroureterectomy
Rouprˆ et et al. compared the outcomes in patients who had
undergone either open nephroureterectomy or endoscopic
surgery (ureteroscopic or percutaneous management) for
upper urinary tract transitional cell carcinoma. A retrospec-
tivereviewofthedataforpatientstreatedsurgicallyforupper
urinary tract transitional cell carcinoma from 1990 to 2004
was performed. Data were analyzed for 97 patients. The sur-
gical procedure was open nephroureterectomy in 54 patients,
ureteroscopy in 27, and percutaneous endoscopic ablation
in 16. In patients with low-grade tumours (n = 46), the 5-
year disease-speciﬁc survival rate after nephroureterectomy,
ureteroscopy, and percutaneous endoscopy was 84%, 80.7%,
and 80%, respectively (P = .89); the corresponding 5-yearAdvances in Urology 5
tumour-freesurvivalrateswere75.3%,71.5%,and72%(P =
.78) [27].
Lee et al. had similar ﬁndings when reviewing their 13
year experience of percuaneous management of upper tract
urothelial carcinoma. They found no signiﬁcant diﬀerence
in overall survival when compared with nephroureterctomy.
Regardless of treatment modality, patients with low grade
lesions did well where as those with high grade lesions were
predisposed to tumour recurrence and progression. Also,
recurrence rates of bladder TCC appear to be similar after
radical nephrectomy or endoscopic surgery [28].
Boorjian et al. reviewed 121 patients who under-
went a nephroureterectomy for upper tract TCC over a
10-year period. In comparing patients who underwent
nephroureterectomy on the basis of positive cytology ﬁnd-
ings and ﬁlling defects on contrast imaging (n = 34) with
patients who had nephroureterectomy after ureteroscopic
biopsy (n = 75) and patients who had nephroureterectomy
after ureteroscopic biopsy and laser ablation (n = 12),
they found no signiﬁcant diﬀerence in postoperative disease
status. Disease free rates in the 3 groups were 85.3%, 81.3%,
and 83.3%, respectively [29].
8. Conclusions
Manyreportsofendoscopicsurgeryforuppertracturothelial
carcinoma have emerged but only a few have a reasonable
number of patients. Most series are small, with all types of
indications (elective and palliative) and tumour characteris-
tics (grade, stage, size, location).
The main message from series of endoscopic man-
agement of upper tract urothelial cancer is that patients
must be carefully selected. Patient selection is based on
tumour size, grade, and multifocality. Single low-grade
tumours, less than 1.5cm in size generally have a good
outcome with endoscopic treatment provided they have
regular ureteroscopic surveillance. Ureteroscopic treatment
of high-grade tumours is essentially palliative. It is essential
that patients are motivated and compliant as lifetime follow-
up is necessary.
Recurrence rates are high but these recurrences can
be treated with further endourological therapy or radical
surgery as studies have shown that endological manipulation
does not have a negative impact on survival.
Theendoscopicapproachcanbemootedasanalternative
approachtonephroureterectomyinpoorperformancestatus
patients, but, until large, randomized trials with long-term
follow-up are performed, it cannot be considered as a
standard treatment.
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